Diabetes Metab J.  2012 Feb;36(1):6-12. 10.4093/dmj.2012.36.1.6.

Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus in Korea

• Ko SH
• Cha BY

• KMID: 2281423
• DOI: http://doi.org/10.4093/dmj.2012.36.1.6

Abstract

Diabetic peripheral neuropathy (DPN), a common and troublesome complication in patients with type 2 diabetes mellitus (T2DM), contributes to a higher risk of diabetic foot ulcer and lower limb amputation. These situations can negatively impact the quality of life of affected individuals. Despite its high prevalence and clinical importance, most diabetes mellitus patients not only do not recognize the presence of diabetic neuropathy, but also do not report their symptoms to physicians or other health care providers. Therefore, DPN is usually under diagnosed and undertreated. For early detection and appropriate intervention for DPN, a careful history, physical with neurologic examination, and prompt treatment are needed in T2DM patients.

Keyword

Diabetes mellitus, type 2; Diabetic neuropathies; Diabetic peripheral neuropathy; Pain

MeSH Terms

Amputation
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetic Foot
Diabetic Neuropathies
Health Personnel
Humans
Korea
Lower Extremity
NAD
Neurologic Examination
Peripheral Nervous System Diseases
Prevalence
Quality of Life
Ulcer
NAD

Reference

1. Kim DJ. The epidemiology of diabetes in Korea. Diabetes Metab J. 2011. 35:303–308.

2. 2009 statistical results about cause of death. Statistics Korea. updated 2011 Sep 5. Available from: http://www.index.go.kr.

3. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011. 94:311–321.

4. Vinik A, Ullal J, Parson HK, Casellini CM. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab. 2006. 2:269–281.

5. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010. 33:2285–2293.

6. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004. 27:1458–1486.

7. Sinnreich M, Taylor BV, Dyck PJ. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist. 2005. 11:63–79.

8. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008. 70:1630–1635.

9. Poncelet AN. Diabetic polyneuropathy. Risk factors, patterns of presentation, diagnosis, and treatment. Geriatrics. 2003. 58:16–18. 24–25. 30

10. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000. 47:123–128.

11. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011. 7:573–583.

12. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care. 1994. 17:557–560.

13. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, Engelgau MM, Kaplan RM, Herman WH. Valuing health-related quality of life in diabetes. Diabetes Care. 2002. 25:2238–2243.

14. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care. 1999. 22:1036–1042.

15. Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M, Caminiti M, Curci V, Quarantiello A, Lupattelli T, Morabito A. Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. Diabetes Care. 2009. 32:822–827.

16. Smith SC, Lamping DL, Maclaine GD. Measuring health-related quality of life in diabetic peripheral neuropathy: a systematic review. Diabetes Res Clin Pract. Epub 2011 Dec 9. DOI: http://dx.doi.org/10.1016/j.diabres.2011.11.013.

17. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006. 29:1518–1522.

18. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004. 21:976–982.

19. Driver VR, Fabbi M, Lavery LA, Gibbons G. The costs of diabetic foot: the economic case for the limb salvage team. J Vasc Surg. 2010. 52:3 Suppl. 17S–22S.

20. Karvestedt L, Martensson E, Grill V, Elofsson S, von Wendt G, Hamsten A, Brismar K. The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden. J Diabetes Complications. 2011. 25:97–106.

21. Won JC, Ko KS. The epidemiology of diabetic neuropathy in Korea. Korean Clin Diabetes. 2010. 11:177–183.

22. Chuang LM, Tsai ST, Huang BY, Tai TY. Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia--a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med. 2002. 19:978–985.

23. Lim S, Kim DJ, Jeong IK, Son HS, Chung CH, Koh G, Lee DH, Won KC, Park JH, Park TS, Ahn J, Kim J, Park KG, Ko SH, Ahn YB, Lee I. A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: the Committee of the Korean Diabetes Association on the Epidemiology of Diabetes Mellitus. Korean Diabetes J. 2009. 33:48–57.

24. Park SA, Ko SH, Lee SH, Cho JH, Moon SD, Jang SA, Son HS, Song KH, Cha BY, Son HY, Ahn YB. Incidence of diabetic foot and associated risk factors in type 2 diabetic patients: a five-year observational study. Korean Diabetes J. 2009. 33:315–323.

25. Ziegler D. Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care. 2009. 32:Suppl 2. S414–S419.

26. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009. 10:393–400.

27. Chung JO, Cho DH, Chung DJ, Chung MY. Association between diabetic polyneuropathy and cardiovascular complications in type 2 diabetic patients. Diabetes Metab J. 2011. 35:390–396.

28. Karvestedt L, Martensson E, Grill V, Elofsson S, von Wendt G, Hamsten A, Brismar K. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care. 2009. 32:317–322.

29. Kim ES, Moon SD, Kim HS, Lim DJ, Cho JH, Kwon HS, Ahn CW, Yoon KH, Kang MI, Cha BY, Son HY. Diabetic peripheral neuropathy is associated with increased arterial stiffness without changes in carotid intima-media thickness in type 2 diabetes. Diabetes Care. 2011. 34:1403–1405.

30. Lee KO, Nam JS, Ahn CW, Hong JM, Kim SM, Sunwoo IN, Moon JS, Na SJ, Choi YC. Insulin resistance is independently associated with peripheral and autonomic neuropathy in Korean type 2 diabetic patients. Acta Diabetol. Epub 2010 Feb 4. DOI: http://dx.doi.org/10.1007/s00592-010-0176-6.

31. Elliott J, Tesfaye S, Chaturvedi N, Gandhi RA, Stevens LK, Emery C, Fuller JH. EURODIAB Prospective Complications Study Group. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care. 2009. 32:1896–1900.

32. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008. 9:660–674.

33. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain. 2000. 16:2 Suppl. S12–S20.

34. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care. 2007. 30:Suppl 1. S4–S41.

35. Canadian Diabetes Association. 2008 Clinical practice guidelines for the prevention and management of diabetes in Canada: neuropathy. Can J Diabetes. 2008. 32:Suppl 1. S140–S142.

36. Korean Diabetes Association. 2011 Treatment guideline for type 2 diabetes. 2011. 4th ed. Seoul: Korean Diabetes Association.

37. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ 3rd, Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993. 43:817–824.

38. Lee S, Kim H, Choi S, Park Y, Kim Y, Cho B. Clinical usefulness of the two-site Semmes-Weinstein monofilament test for detecting diabetic peripheral neuropathy. J Korean Med Sci. 2003. 18:103–107.

39. Shin JB, Seong YJ, Lee HJ, Kim SH, Park JR. Foot screening technique in a diabetic population. J Korean Med Sci. 2000. 15:78–82.

40. McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, Pecoraro RF. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care. 1995. 18:216–219.

41. An JY, Park MS, Kim JS, Shon YM, Lee SJ, Kim YI, Lee KS, Kim BJ. Comparison of diabetic neuropathy symptom score and medial plantar sensory nerve conduction studies in diabetic patients showing normal routine nerve conduction studies. Intern Med. 2008. 47:1395–1398.

42. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D. American Academy of Neurology. American Association of Neuromuscular and Electrodiagnostic Medicine. American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011. 76:1758–1765.

43. Jin HY, Joung SJ, Park JH, Baek HS, Park TS. The effect of alpha-lipoic acid on symptoms and skin blood flow in diabetic neuropathy. Diabet Med. 2007. 24:1034–1038.

44. Hahm JR, Kim BJ, Kim KW. Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. J Diabetes Complications. 2004. 18:79–85.

45. Ko SH, Kwon HS, Yu JM, Baik SH, Park IB, Lee JH, Ko KS, Noh JH, Kim DS, Kim CH, Mok JO, Park TS, Son HS, Cha BY. Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. Diabet Med. 2010. 27:1033–1040.

46. Moon DE, Lee DI, Lee SC, Song SO, Yoon DM, Yoon MH, Kim HK, Lee YW, Kim C, Lee PB. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010. 32:2370–2385.

47. Daousi C, Benbow SJ, Woodward A, MacFarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med. 2006. 23:1021–1024.